Published in Nature on August 18, 2011
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science (2012) 6.79
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Links between metabolism and cancer. Genes Dev (2012) 5.27
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
Oxidative stress inhibits distant metastasis by human melanoma cells. Nature (2015) 3.87
Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature (2014) 3.80
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77
Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 3.62
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Passenger deletions generate therapeutic vulnerabilities in cancer. Nature (2012) 3.11
Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (2012) 3.05
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature (2012) 3.01
Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science (2012) 2.98
Quantitative flux analysis reveals folate-dependent NADPH production. Nature (2014) 2.93
Cellular metabolism and disease: what do metabolic outliers teach us? Cell (2012) 2.90
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell (2014) 2.66
Metabolic regulation of epigenetics. Cell Metab (2012) 2.55
Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell (2013) 2.55
Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol (2015) 2.35
The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell (2016) 2.28
Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell (2013) 2.27
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med (2013) 2.27
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature (2014) 2.27
Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 2.27
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature (2016) 2.11
Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A (2012) 2.10
Insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1. PLoS Biol (2015) 2.07
Cancer metabolism: current perspectives and future directions. Cell Death Dis (2012) 2.07
Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed (2012) 2.06
Cell biology. Metabolic control of cell death. Science (2014) 1.98
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol (2012) 1.96
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Metabolic Heterogeneity in Human Lung Tumors. Cell (2016) 1.86
Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol (2016) 1.83
Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun (2014) 1.75
Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest (2015) 1.74
Essential nontranslational functions of tRNA synthetases. Nat Chem Biol (2013) 1.72
Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells. Mol Cell (2016) 1.71
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet (2012) 1.70
Serine and glycine metabolism in cancer. Trends Biochem Sci (2014) 1.70
Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) (2012) 1.66
Targeting glucose metabolism for cancer therapy. J Exp Med (2012) 1.64
NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet (2015) 1.60
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis (2013) 1.57
Mitochondrial dysfunction in cancer. Front Oncol (2013) 1.57
Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov (2014) 1.53
Resurgence of serine: an often neglected but indispensable amino Acid. J Biol Chem (2012) 1.51
Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. Cancer Metab (2014) 1.48
A mitochondrial RNAi screen defines cellular bioenergetic determinants and identifies an adenylate kinase as a key regulator of ATP levels. Cell Rep (2014) 1.48
NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol (2013) 1.46
Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res (2012) 1.46
Exploiting the bad eating habits of Ras-driven cancers. Genes Dev (2013) 1.45
A roadmap for interpreting (13)C metabolite labeling patterns from cells. Curr Opin Biotechnol (2015) 1.44
Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. Cell (2013) 1.44
Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem Sci (2015) 1.42
Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med (2013) 1.39
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal (2014) 1.37
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem (2012) 1.36
Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet (2012) 1.31
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30
Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther (2011) 1.29
Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab (2012) 1.28
Stable RNA interference rules for silencing. Nat Cell Biol (2014) 1.26
Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol (2012) 1.24
Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. Hum Mol Genet (2013) 1.23
Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol (2012) 1.23
SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature (2015) 1.22
Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson. Nat Med (2012) 1.22
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) is a pro-survival, endoplasmic reticulum (ER) stress response gene involved in tumor cell adaptation to nutrient availability. J Biol Chem (2014) 1.21
Characterization of the usage of the serine metabolic network in human cancer. Cell Rep (2014) 1.20
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ (2012) 1.19
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab (2013) 1.18
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem Biol (2014) 1.15
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat (2013) 1.13
Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell (2014) 1.12
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2013) 1.12
Interactions between epigenetics and metabolism in cancers. Front Oncol (2012) 1.11
The proline regulatory axis and cancer. Front Oncol (2012) 1.10
Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol Med (2012) 1.10
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab (2013) 1.09
Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol Metab (2012) 1.09
Fundamentals of cancer metabolism. Sci Adv (2016) 1.09
Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res (2015) 1.08
Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U S A (2016) 1.08
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol (2015) 1.08
Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS One (2011) 1.08
Life in the fast lane: mammalian disease models in the genomics era. Cell (2012) 1.08
Phosphatidic acid and lipid-sensing by mTOR. Trends Endocrinol Metab (2013) 1.07
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J Neurooncol (2012) 1.07
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst (2000) 3.44
Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (2009) 3.14
Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst (1993) 3.03
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat (2010) 2.40
Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Adv Enzyme Regul (1984) 2.35
Purification and properties of chicken liver D-3-phosphoglycerate dehydrogenase. Biochemistry (1965) 2.08
Cloning, sequencing and expression of rat liver 3-phosphoglycerate dehydrogenase. Biochem J (1997) 1.78
Phosphoserine phosphatase distribution in normal and neoplastic rat tissues. Arch Biochem Biophys (1969) 1.68
The reactions of the phosphorylated pathway of L-serine biosynthesis: thermodynamic relationships in rabbit liver in vivo. Arch Biochem Biophys (1985) 1.44
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
mTOR signaling in growth control and disease. Cell (2012) 29.21
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
CellProfiler: free, versatile software for automated biological image analysis. Biotechniques (2007) 14.71
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature (2011) 11.31
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics (2004) 8.29
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36